Wealthfront Advisers
MRNA icon

Wealthfront Advisers’s Moderna MRNA Stock Holding History

Wealthfront Advisers’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Sell
15,621
-4,623
-23% -$239K ﹤0.01% 706
2026
Q1 		$1.03M Buy
20,244
+6,508
+47% +$304K ﹤0.01% 711
2025
Q4 		$405K Sell
13,736
-3,712
-21% -$101K ﹤0.01% 861
2025
Q3 		$451K Sell
17,448
-1,439
-8% -$40.1K ﹤0.01% 834
2025
Q2 		$521K Sell
18,887
-12,131
-39% -$319K ﹤0.01% 786
2025
Q1 		$879K Buy
31,018
+18,268
+143% +$648K ﹤0.01% 684
2024
Q4 		$530K Sell
12,750
-161
-1% -$7.7K ﹤0.01% 771
2024
Q3 		$863K Sell
12,911
-9,172
-42% -$842K ﹤0.01% 672
2024
Q2 		$2.62M Buy
22,083
+8,081
+58% +$1.02M 0.01% 419
2024
Q1 		$1.49M Buy
14,002
+9,003
+180% +$907K 0.01% 539
2023
Q4 		$497K Buy
+4,999
New +$420K ﹤0.01% 719
2023
Q2 		– Sell
-16,804
Closed -$2.58M – 836
2023
Q1 		$2.58M Sell
16,804
-8,005
-32% -$1.32M 0.01% 358
2022
Q4 		$4.46M Buy
24,809
+15,666
+171% +$2.56M 0.02% 223
2022
Q3 		$1.08M Sell
9,143
-6,162
-40% -$935K 0.01% 473
2022
Q2 		$2.19M Sell
15,305
-12,877
-46% -$1.84M 0.01% 357
2022
Q1 		$4.86M Sell
28,182
-5,519
-16% -$929K 0.02% 213
2021
Q4 		$8.56M Buy
33,701
+3,815
+13% +$1.12M 0.04% 117
2021
Q3 		$11.5M Buy
29,886
+24,157
+422% +$8.91M 0.05% 73
2021
Q2 		$1.35M Buy
+5,729
New +$1.02M 0.01% 382

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Wealthfront Advisers's MRNA Position: Q2 2026 in Review

Wealthfront Advisers reduced its Moderna (MRNA) stake by 23% in Q2 2026, selling an estimated $239K and leaving 15,621 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #706.

Wealthfront Advisers first reported a position in MRNA in Q2 2021 and has held it in 19 quarters since. The position peaked at $11.5M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Wealthfront Advisers held 15,621 shares of Moderna worth $1.09M as of Q2 2026.
  • Wealthfront Advisers sold 4,623 Moderna shares in Q2 2026, an estimated $239K.
  • Moderna made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #706 holding.
  • Wealthfront Advisers first reported a position in Moderna in Q2 2021 and has held it in 19 quarters since.
  • Wealthfront Advisers's Moderna position peaked at $11.5M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.